Vgat Vesicular Gaba Transporter Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
VGAT (Vesicular GABA Transporter), also known as SLC32A1, is responsible for transporting GABA and glycine into synaptic vesicles, enabling inhibitory neurotransmission throughout the central nervous system. VGAT-expressing neurons constitute the primary inhibitory network, regulating neural excitability, network oscillations, and information processing. Mutations in VGAT have been implicated in epilepsy, hyperekplexia, and various neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) 1. [1]
| Property | Details | [2]
|----------|---------| [3]
| Gene Symbol | SLC32A1 | [4]
| Chromosome | 20q11.23 | [5]
| Protein Size | 525 amino acids | [6]
| Topology | 10 transmembrane domains |
| Family | Major facilitator superfamily (MFS) |
VGAT operates as a H+/GABA antiporter, using the proton gradient established by V-ATPase to drive GABA and glycine uptake into synaptic vesicles. The transport cycle involves:
| Substrate | Affinity (Km) | Vesicle Type |
|---|---|---|
| GABA | 0.2-0.5 mM | GABAergic vesicles |
| Glycine | 0.5-1.0 mM | Glycinergic vesicles |
| Beta-alanine | 2-5 mM | Alternative substrate |
| Taurine | 5-10 mM | Low-affinity substrate |
VGAT-expressing neurons are广泛分布 throughout the CNS:
| Type | Location | Function |
|---|---|---|
| Parvalbumin (PV+) | Cortex, hippocampus | Fast-spiking, perisomatic inhibition |
| Somatostatin (SST+) | Cortex, hippocampus | Dendritic inhibition |
| Calretinin (CR+) | Cortex | Late-spiking interneurons |
| VIP+ | Cortex | Disinhibition, interneuron circuits |
GABAergic signaling through VGAT neurons produces:
VGAT neurons are affected in AD through multiple mechanisms:
| Drug Class | Mechanism | Application |
|---|---|---|
| Benzodiazepines | GABA_A positive modulators | Anxiety, seizures, sedation |
| Barbiturates | GABA_A agonists | Seizures, anesthesia |
| Tiagabine | GABA transporter blocker | Epilepsy |
| Vigabatrin | GABA transaminase inhibitor | Seizures, infantile spasms |
| Baclofen | GABA_B agonists | Spasticity, addiction |
Current research focuses on:
Vgat Vesicular Gaba Transporter Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Vgat Vesicular Gaba Transporter Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Palop JJ et al. Inhibitory interneurons in AD (2011). 2011. ↩︎
Djekidel ME et al. VGAT mutations in epilepsy (2011). 2011. ↩︎
McIntire SL et al. VGAT identification (1997). 1997. ↩︎
Wojcik SM et al. Synaptic vesicle filling (2006). 2006. ↩︎
Rossi S et al. GABAergic dysfunction in ALS (2018). 2018. ↩︎
Soh H et al. GABAergic signaling in HD (2020). 2020. ↩︎